MDS
Advertisement
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
Overall survival, nonrelapse mortality, and relapse rates were also assessed in the phase 2 trial which had these results.
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Juan Jose Rodriguez-Sevilla, MD, PhD, summarizes current clinical knowledge about inflammation within MDS pathobiology.
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.
Daily oral administration of the agent brought favorable transfusion independence performance and overall safety.
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.